ROS1 and melanoma: The pronounced clinical benefits derived from ROS1 mutation versus wild type were furtherly confirmed in the MEL-IPI cohort of melanoma treated with ipilimumab (HR 0.55, 95% CI 0.34–0.91; P = 0.046, Figure 2F).